Proposed Complementary Health Products Regulation

The Health Sciences Authority (HSA) consulted on a proposed regulatory framework for Complementary Health Products (CHP) under Singapore's Health Products Act. The consultation ran from 1 to 29 July 2026. HSA describes the proposal as a future framework, not enacted amendments already applying to every CHP (HSA, 1 July 2026).

Products and current baseline

HSA describes CHP as self-care products containing ingredients with a long history of safe use, intended to support general health or alleviate minor symptoms consumers can manage themselves. The consulted categories include health supplements, traditional medicines excluding traditional Chinese medicines, homeopathic medicines, medicated oils, balms and plasters, and topical antiseptics (HSA, 1 July 2026).

At the time of consultation, CHP were regulated under the Medicines Act with a light-touch approach: they were not subject to pre-market product evaluation or licensing of manufacturers, importers and suppliers, although HSA imposed safety and quality requirements and used post-market surveillance. HSA separately stated that traditional Chinese medicinal products would follow a separate Health Products Act framework from early 2027 (HSA, 1 July 2026).

Proposed controls

HSA proposed moving the remaining medicinal-product controls in the CHP scope from the Medicines Act to the Health Products Act by the end of 2028. The proposal would maintain light-touch pre-market controls while strengthening product safety, quality and labelling requirements and the duties of manufacturers, importers and suppliers (HSA, 1 July 2026).

The consultation covered six areas: product notification; product safety and quality; product labelling; record keeping and safety reporting; advertisement controls; and the implementation timeline. HSA also proposed that a person instrumental in placing a CHP on the local market notify HSA of key product information, supporting traceability, post-market surveillance and timely regulatory action when safety issues are detected (HSA, 1 July 2026).

Interpretation boundary

This proposal should not be confused with HSA's existing List of Notified Complementary Health Products. That list records voluntary company notifications and is not HSA product approval or endorsement (HSA, List of Notified Complementary Health Products, accessed 12 September 2026). The 2026 consultation concerned a possible statutory framework; its consultation date and proposed end-2028 migration plan do not prove that the final rules, scope or commencement will be identical to the proposal.

The distinction is especially important for consumers and businesses using the words “registered”, “notified” or “approved”. HSA's current list is based on voluntary company declarations against published guidelines, whereas the consultation proposed future statutory notification and traceability duties; neither wording alone establishes that HSA has assessed a product's therapeutic effectiveness (HSA, notified products, updated 11 September 2026; HSA, consultation, updated 11 September 2026).

Status and practical interpretation

The consultation page records HSA's proposed direction and the feedback window, while the separate notified-products page continues to describe voluntary company declarations and expressly says that notification is not HSA endorsement (HSA, consultation, updated 11 September 2026; HSA, notified products, updated 11 September 2026). A product appearing on the voluntary list therefore does not demonstrate that the proposed Health Products Act controls have commenced, that HSA has evaluated the product for efficacy, or that the product may make disease-treatment claims. For a current compliance decision, identify the product category, the applicable operative legislation and the latest HSA guidance rather than relying on the consultation proposal alone.